avatromopag治疗成人免疫性血小板减少症：西班牙马德里的一项多中心现实观察研究（AVAMAD研究）。

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2025-01-05 DOI:10.1111/bjh.19975

Cristina Pascual-Izquierdo, Mª Jose Llacer-Ferrandis, Almudena de-la-Iglesia, Silvia Monsalvo-Saornil, María Menor-Gómez, Juan Jose Gil-Fernández, Esther Chica-Gullon, María Teresa Álvarez-Román, Gloria Perez-Segura, Denis Zafra, Ariana Ortuzar-Pasalodos, Isabel Teresa González-Gascón-Y-Marín, Gemma Moreno, Teresa Arquero-Portero, Marta Moreno-Carbonell, Nuria Revilla

{"title":"avatromopag治疗成人免疫性血小板减少症：西班牙马德里的一项多中心现实观察研究（AVAMAD研究）。","authors":"Cristina Pascual-Izquierdo, Mª Jose Llacer-Ferrandis, Almudena de-la-Iglesia, Silvia Monsalvo-Saornil, María Menor-Gómez, Juan Jose Gil-Fernández, Esther Chica-Gullon, María Teresa Álvarez-Román, Gloria Perez-Segura, Denis Zafra, Ariana Ortuzar-Pasalodos, Isabel Teresa González-Gascón-Y-Marín, Gemma Moreno, Teresa Arquero-Portero, Marta Moreno-Carbonell, Nuria Revilla","doi":"10.1111/bjh.19975","DOIUrl":null,"url":null,"abstract":"Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study).\",\"authors\":\"Cristina Pascual-Izquierdo, Mª Jose Llacer-Ferrandis, Almudena de-la-Iglesia, Silvia Monsalvo-Saornil, María Menor-Gómez, Juan Jose Gil-Fernández, Esther Chica-Gullon, María Teresa Álvarez-Román, Gloria Perez-Segura, Denis Zafra, Ariana Ortuzar-Pasalodos, Isabel Teresa González-Gascón-Y-Marín, Gemma Moreno, Teresa Arquero-Portero, Marta Moreno-Carbonell, Nuria Revilla\",\"doi\":\"10.1111/bjh.19975\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/bjh.19975\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.19975","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

免疫性血小板减少症（ITP）是一种罕见的后天性疾病，促血小板生成素受体激动剂已成为治疗 ITP 的主要药物。随着阿伐曲波帕（AVA）最近获得批准，对其疗效和安全性进行真实世界研究至关重要。我们对 66 名接受 AVA 治疗的成年 ITP 患者进行了研究，结果显示反应率很高。开始使用 AVA 后，74.2% 的患者无需使用抢救药物，且不良反应极小。此外，56.0%的患者减少了其他ITP药物的使用，所有年龄≥65岁的患者都对AVA产生了反应。研究结果有待更大规模的研究证实，但 AVA 似乎是治疗 ITP 患者的一种有效而安全的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study).

Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.